

Special Issue

Early Diagnosis of Cancer

Message from the Guest Editors

The early diagnosis of cancer, before it has metastasised, is key to more effective—and often curative—treatment. For example, more than 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least 5 years compared to around 15% for women diagnosed with the most advanced stage of disease. Making improvements in early cancer diagnosis covers a wide range of scientific disciplines, including fundamental research that aims to identify premalignant drivers of tumourigenesis or markers of early disease, translational studies that find ways to apply that research to the disease, and research into implementing advances in early diagnosis into the clinical pathway. This Special Issue will highlight state-of-the-art research in improving the early diagnosis of cancers towards advancing the clinical impact of existing scientific knowledge.

Guest Editors

Dr. Hayley C. Whitaker

Division of Surgery & Interventional Science, University College London, London WC1E 6BT, UK

Dr. Kelly Coffey

Translational and Clinical Research Institute, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK

Deadline for manuscript submissions

closed (30 March 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/93840

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)